CONTEXT: Commercial announcement of a study conducted in the Real-world on a HCV test. Small numbers of patients involved and no details of the research, so by way of caution, Continue Reading
CONTEXT: Novrtis going old school with the announcement of a global Phase 3b study in children with spinal muscular atrophy (SMA). Respect to Novartis for making the announcement and calling Continue Reading
CONTEXT: A very well put together and clearly well researched opinion piece promoting RWD as the basis for COVID decision making in the US. Interesting highlight of what is termed Continue Reading
CONTEXT: Commercial announcement of an RWE report updated for 2020 to 2030 claiming to cover a wide range of information about providers of RWE services and future trends in RWE. Continue Reading
CONTEXT: RWR shows reduced exacerbations, MG crises and hospitalisations in myasthenia Gravis patients (MG) who were on eculizumab (Soliris) in a real-world study presented at the virtual AAN annual meeting Continue Reading
CONTEXT: RWD, in this case US claims database, used to analyse disease progression measures for patients on edaravone (Radical). Results were presented at the AAN virtual meeting. This report does Continue Reading
CONTEXT: It’s awards season and as we wait to see who will be glammed up from the waist up at the Oscars, another RWE report is issued with even bigger Continue Reading
CONTEXT: Relatively small scale retrospective analysis of IPF patients in Japan reveals outcomes are poor for patients developing progressive fibrosing interstitial lung disease (PF-ILD) other than idiopathic pulmonary fibrosis (IPF). IMPACT: Low Continue Reading
CONTEXT: Another commercial announcement of a tie up on RWD sources | US only. IMPACT: Low READ TIME: 1 min Quality Level Mean [1 – 10]: 3 1. “Through the Continue Reading
CONTEXT: An august meeting of medical societies in Brussels to debate a few interesting topics for our discerning readers | Firstly the implications of the new IVD regulations which are definitely Continue Reading
